Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL215 Target Snapshot

Polyunsaturated fatty acid 5-lipoxygenase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,519Compounds
827Assays
7Approved Drugs
4,326.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Polyunsaturated fatty acid 5-lipoxygenase shows approved-linked disease relevance led by ulcerative colitis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P09917. Start with ulcerative colitis, then reuse UniProt P09917 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with ulcerative colitis, then reuse UniProt P09917 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 4 linked drugs
Open source guide
Disease program
ulcerative colitis

Polyunsaturated fatty acid 5-lipoxygenase shows approved-linked disease relevance led by ulcerative colitis. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with ulcerative colitis because it currently carries approved-linked support. Linked drugs include BALSALAZIDE DISODIUM, MESALAMINE, OLSALAZINE SODIUM, SULFASALAZINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Polyunsaturated fatty acid 5-lipoxygenase as ChEMBL target CHEMBL215, mapped to UniProt P09917. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Polyunsaturated fatty acid 5-lipoxygenase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL215
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P09917
Polyunsaturated fatty acid 5-lipoxygenase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Polyunsaturated fatty acid 5-lipoxygenase is the right protein anchor across sources, using UniProt P09917 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why ulcerative colitis is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamePolyunsaturated fatty acid 5-lipoxygenase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP09917
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPolyunsaturated fatty acid 5-lipoxygenase
UniProt AccessionP09917
Component TypeProtein
Sequence Length674 aa

Polyunsaturated fatty acid 5-lipoxygenase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Polyunsaturated fatty acid 5-lipoxygenase, mapped to UniProt P09917. Sequence length is 674 aa.

Mapped IDP09917
Review namePolyunsaturated fatty acid 5-lipoxygenase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Polyunsaturated fatty acid 5-lipoxygenase shows approved-linked disease relevance led by ulcerative colitis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
ulcerative colitis
4 linked drugs · 4 direct · 4 efficacy
Linked drugBALSALAZIDE DISODIUM
Linked drugMESALAMINE
Linked drugOLSALAZINE SODIUM
Linked drugSULFASALAZINE
Approved-linked Approved
asthma
2 linked drugs · 2 direct · 2 efficacy
Linked drugPF-4191834
Linked drugZILEUTON
Approved-linked Approved
juvenile idiopathic arthritis
2 linked drugs · 2 direct · 2 efficacy
Linked drugMECLOFENAMATE SODIUM
Linked drugSULFASALAZINE
Approved-linked Approved
rheumatoid arthritis
2 linked drugs · 2 direct · 2 efficacy
Linked drugMECLOFENAMATE SODIUM
Linked drugSULFASALAZINE
Approved-linked Approved
Dysmenorrhea
1 linked drug · 1 direct · 1 efficacy
Linked drugMECLOFENAMATE SODIUM
Approved-linked Approved
Fever
1 linked drug · 1 direct · 1 efficacy
Linked drugMECLOFENAMATE SODIUM
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with ulcerative colitis because it currently carries approved-linked support. Linked drugs include BALSALAZIDE DISODIUM, MESALAMINE, OLSALAZINE SODIUM, SULFASALAZINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseulcerative colitis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

7
Approved
7
Phase III
20
Phase II
1
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC504,251.0
KI13.0
EC5062.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL205800 9.3 IC50 0.5 Preclinical
CHEMBL377821 9.3 IC50 0.5 Preclinical
CHEMBL377094 9.1 IC50 0.8 Preclinical
CHEMBL204365 9.05 IC50 0.9 Preclinical
CHEMBL16596 8.8 IC50 1.6 Clinical
CHEMBL205189 8.72 IC50 1.9 Preclinical
CHEMBL207057 8.64 IC50 2.3 Preclinical
CHEMBL205222 8.57 IC50 2.7 Preclinical
CHEMBL194522 8.52 EC50 3.0 Preclinical
CHEMBL207109 8.52 IC50 3.0 Preclinical
Distribution

pChEMBL Value Distribution

546
5.0
699
5.5
822
6.0
590
6.5
383
7.0
166
7.5
39
8.0
11
8.5
4
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

ZILEUTON
CHEMBL93
Approved 1996
Properties Compare Identifier
Assay Landscape

Assay Landscape

827
Total Assays
2,343
Tested Compounds
3
Assay Types
Binding — 738 assays, 2,343 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 387 1,047 6.0
assay format 164 688 6.2
cell-based format 129 422 6.1
tissue-based format 49 185 6.1
organism-based format 9 1 6.4
Functional — 88 assays, 510 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 48 0 —
assay format 20 288 6.9
tissue-based format 19 186 6.4
cell-based format 1 36 5.4
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine